Highest-materiality recent filing
Ensysce gets Nasdaq extension on bid price; Cy deal triggers initial listing review
Nasdaq confirmed compliance with $2.5M stockholders' equity (Rule 5550(b)(1)) but requires evidence in next periodic report or delisting.
Ensyce raises $21M initial tranche of $43M Series C financing; Nasdaq compliance update
Initial closing Aug 7, 2026 raised >$21M gross; issued 120,260 Series C preferred shares.
Ensysce Q2 net loss $2.6M; completes Cy Biopharma acquisition adding CY200, $77M funding
Completed acquisition of Cy Biopharma on Aug 6, 2026, adding CY200 (Orphan Drug-designated for CRPS) as lead asset; up to $77M in new funding.
Ensysce acquires Cy Biopharma and up to $77M private financing for CRPS drug
Acquisition of Cy Biopharma includes clinical-stage neuroplastogenic therapy CY200 for CRPS with FDA Orphan Drug Designation.
Ensysce acquires Cy Biopharma, issues Series C Preferred, raises ~$43M in PIPE
Acquired Cy Biopharma on Aug 5, 2026; Cy stockholders received 282,122 shares of Series C Preferred Stock (convertible 1:1,000 into common).
Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026
Jeffrey Millard resigned as Chief Operating Officer on July 10, 2026.
Nasdaq notifies Ensysce of delisting risk for equity shortfall
Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway
Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55
Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
Director Curtis Rosebraugh resigns from Ensysce Biosciences board
Resignation effective April 1, 2026; no reason given in notice.
Director Lee Rauch resigns from Ensysce board over severance package dispute
Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.
Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial
Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.
Ensysce corrects scrivener's error in Series B Preferred Stock designation
Filed Certificate of Correction on March 18, 2026 to fix a scrivener's error in the Series B Preferred Stock designation.
Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1
Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.
Ensysce shareholders approve share issuance to investor and incentive plan increase
Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.
Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available
Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR
Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614
Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
Ensysce Biosciences auditor changes to Baker Tilly after Moss Adams merger
Moss Adams merged into Baker Tilly effective June 3, 2025; Baker Tilly appointed as successor auditor.
Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares
Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.
Ensysce corrects auditor consent to include omitted S-3 registration statements
Original consent filed March 10, 2025 with Form 10-K omitted references to Registration Statements No. 333-275456 and No. 333-276537.
Ensysce Biosciences closes $1.1M registered direct offering and private placement of warrants
Gross proceeds of approximately $1.1M from sale of 315,188 shares (or equivalents) at $3.49/share.
Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner
Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal
Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
Ensysce Biosciences announces 1-for-15 reverse stock split effective Dec 6, 2024
Reverse stock split at 1-for-15 ratio, effective 12:01 am on December 6, 2024.
Approved issuance of shares/warrants to investors: 3,102,053 for, 210,141 against (3,995,063 broker non-votes).
Ensysce reports Q3 net income of $0.7M; awarded $14M NIH grant for PF614-MPAR
Net income of $0.7M vs net loss of $2.7M in Q3 2023; driven by $3.4M in federal grant revenue.
Ensysce Biosciences reduces stockholder quorum to 1/3 of votes, effective Nov 1, 2024
Bylaw amendment lowers quorum from majority to 1/3 of total votes entitled to be cast.
Ensysce Biosciences raises $5M in concurrent registered direct offering and warrant exercise
Gross proceeds of $5M from sale of 3.55M shares (or equivalents) at $0.47 per share and exercise of 7.2M outstanding warrants at reduced price.
Ensysce Biosciences receives Nasdaq delisting notice for equity shortfall
Notice received August 20, 2024; non-compliance with $2.5 million stockholders' equity minimum as of June 30, 2024.
Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance
Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.
Ensysce regains Nasdaq compliance with equity requirement, common stock continues trading
Received notice on May 24, 2024 from Nasdaq of regained compliance with Listing Rule 5550(b)(1) equity requirement.
Ensysce Biosciences reports Q1 net loss of $3.1M; advances PF614 Phase 3 plans
Net loss attributable to common stockholders was $3.1M for Q1 2024, vs $2.2M in Q1 2023.
Company believes it now has at least $2.5M stockholders' equity, satisfying Nasdaq listing rule.
Received Nasdaq deficiency letter on March 27, 2024 for bid price closing below $1.00 for 30 consecutive business days.
Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR
Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).
Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06
Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.
Ensysce Biosciences special meeting canceled again due to lack of quorum; no vote on matters
Special meeting of stockholders scheduled for December 29, 2023 was not held due to lack of quorum.
Ensysce Biosciences postpones special meeting to Dec 29 due to quorum shortfall
Special Meeting postponed from Dec 20 to Dec 29, 2023 at 9:00 a.m. PT.
Ensysce completes $1.7M convertible note financing; second closing of $1.133M
Total gross proceeds of $1.7M from senior secured convertible notes and warrants; second closing on Nov 28/29, 2023 added $1.133M (net).
Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.
Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end
Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.
Ensysce Biosciences raises $1.7M in convertible note and warrant private placement
Aggregate investment of $1.7M through senior secured convertible notes and warrants; initial close of $566,667 on or before Oct 26.
Ensysce shareholders elect directors, approve share increase, ratify auditor at annual meeting
Class II directors Bob Gower and Curtis Rosebraugh elected with 222,281 and 223,255 votes for, respectively.
Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study
Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).
Ensysce Biosciences regains compliance with Nasdaq equity requirement on June 13
Received formal notice from Nasdaq that it now meets the equity requirement under Listing Rule 5550(b)(1).
Ensysce completes $7M offering, believes it meets Nasdaq equity requirement
Raised ~$7M gross via public offering of common stock and warrants on May 12, 2023.
Ensysce closes $7M public offering of common stock and warrants
Offered 1,800,876 shares (or pre-funded warrants) plus Series A-1/A-2 warrants at $3.887 per unit.
Ensysce Biosciences dismisses Mayer Hoffman McCann, appoints Moss Adams as auditor
Appointed Moss Adams LLP as independent registered public accounting firm effective April 10, 2023.
the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing
appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.
the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing
on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.
The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.
tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.
On February 8, 2022, the Board of Ensysce Biosciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Lee Rauch to its Board of Directors (“Board”), effective immediately (the “New Director”).
Max materiality 0.85 · Median 0.60 · Most common event other_material